The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
分析师的判决：4位专家眼中的Corcept疗法
In the preceding three months, 4 analysts have released ratings for Corcept Therapeutics (NASDAQ:CORT), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，有4位分析师公布了Corcept Therapeutics（纳斯达克股票代码：CORT）的评级，提出了从看涨到看跌的各种观点。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $41.0, along with a high estimate of $44.00 and a low estimate of $38.00. This current average reflects an increase of 6.03% from the previous average price target of $38.67.
分析师提供了更深入的见解，确定了12个月的目标股价，平均目标价为41.0美元，最高估计为44.00美元，低估值为38.00美元。目前的平均价格比之前的38.67美元的平均目标股价上涨了6.03％。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析师评级：深度探索
The standing of Corcept...
通过对分...
登录免费看全文
登录/注册